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SUMMARY 
Background: Estrogens are established enhancers of breast cancer development and progression, 
but less is known on the effects on migration and metastasis. We studied the actions of estrogens on 
actin cytoskeleton and cell movement and invasion in breast cancer cells. Moreover, we 
characterized the signaling steps through which these actions are enacted 
 
Methodology/Principal Findings: In estrogen receptor (ER) positive T47-D breast cancer cells 
17β-estradiol induces rapid and dynamic actin cytoskeleton remodeling with a loss of stress fibers 
and the formation of the specialized membrane structures like membrane ruffles, pseudopodia and 
lamellipodia. These effects depend on the rapid activation of the actin-binding protein moesin. 
Moesin activation by estradiol is related to the interaction of ERα with the G protein Gα13, which 
results in the recruitment of the small GTPase RhoA and in the subsequent activation of its 
downstream effector Rho-associated kinase-2 (ROCK-2). ROCK-2 is responsible for moesin 
phosphorylation. The recruitment of the Gα13/RhoA/ROCK/moesin cascade is necessary for the 
enhancement of breast cancer cell horizontal migration and invasion of three-dimensional matrices 
by estrogen. In addition, human samples of normal breast tissue, benign fibroadenomas and 
invasive ductal carcinomas show that the expression of wild-type moesin as well as of its active 
form is deranged in cancers, with increased protein amounts and a loss of association with the cell 
membrane. 
 
Conclusions/Significance: These results provide an original mechanism through which estrogen 
can alter the progression of breast cancer, identifying the nongenomic Gα13/RhoA/ROCK/moesin 
signaling cascade as a target of ERα in breast cancer cells. This information helps to understand the 
effects of estrogens on breast cancer metastasis and they may provide new targets for therapeutic 
interventions. 
 
 
 
 
 
 
 
 
 
 2
Maria Silvia Giretti                                                                        ERα, moesin and BC movement 
INTRODUCTION 
 
One out of eight women develop breast cancer at some stage throughout life (1). Despite the recent 
improvements in survival rates, many patients relapse, and the majority of these patients die for 
disseminated metastatic disease, which supports the need for new therapeutic strategies. 
 
In the mammary gland, the sex steroid estrogen promotes breast growth and development at puberty 
and during the menstrual cycle and pregnancy (2). In addition to these physiological effects, 
estrogen plays a major role in the development and progression of breast cancer. Prolonged 
exposure to estrogen, i.e. early menarche, late menopause or postmenopausal hormone replacement 
therapy, is associated with a greater risk of developing breast cancer (3). Estrogen promotes breast 
cancer proliferation through a number of well established pathways (4). On the contrary, the effects 
of estradiol on tumor cell motility and invasion are poorly understood. 
 
Cell movement is a highly integrated molecular process that plays a central role in a wide variety of 
biological phenomena, representing a key aspect of many normal and abnormal processes (5). In 
embryogenesis, cell migration is a recurring phenomenon in important morphogenic events ranging 
from gastrulation to the development of the nervous system (6). Cell motility is also prominent in 
the adult organism, in physiological and pathological conditions. For example, cell movement is 
required in the inflammatory and immune response for leukocytes or lymphocytes to migrate into 
tissues  (7). Wound healing requires fibroblast and vascular endothelial cell movement to achieve 
tissue repair. Angiogenesis requires movement of vascular cells, as well. Even more importantly, 
cell movement is the basis for local cancer invasion and distant metastasis, which represent the 
main reason of morbidity and mortality for malignancies (8). 
 
Although the cellular mechanisms behind cell movement are extremely complex, a critical role in 
the generation of motility force is played by the dynamic remodelling of the actin cytoskeleton, 
which forms the backbone of every cell (9). In addition to this, dynamic changes of the cytoskeleton 
are related to the ability of the cell to respond to external signals from the surrounding environment 
and result in the recruitment of specific intracellular signalling cascades. 
 
The cytoskeleton is an organized structure formed by the connection of three different types of 
filaments: actin, microtubules and intermediate filaments. These cytoskeletal complexes interact 
together as a dynamic network contributing to cell functions such as structural integrity, shape, 
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division and cell motility. Indeed, in most animal cells, the cytoskeleton is the primary actor in 
creating the driving forces through which cells move(10) (11). Actually, although other non-actin 
cytoskeletal complexes aid in coordinating cell movement and in empowering translocation, the 
actin cytoskeleton through highly dynamic remodelling and continuous creation of new actin 
networks is considered essential for pushing the cell forward in the surrounding  environment(12), 
especially at front-membrane cell protrusions that allow the very first steps of cell motility. This 
restructuring of cell shape is achieved with the help of a number of accessory proteins and signaling 
pathways (12) that mediate signals of growth factor and cytokines. 
In this context, we have recently described how the rapid exposure of human endothelial cells to 
physiological level of estradiol leads to a rapid remodelling of actin cytoskeleton with a loss of 
stress fibres and the formation of cortical actin complexes  (13).This cytoskeletal rearrangement, 
associated with the development of specialized cell membrane structures such as ruffles and 
pseudopodia, is obtained through the activation of the actin-regulatory protein, moesin  (13). A 
number of studies have underlined the fundamental contribution of the ezrin-radixin-moesin (ERM) 
family of proteins to cytoskeletal processes responsible for many vital cellular functions such as cell 
motility(14).We have described how the activation of moesin is rapidly triggered by a complex of 
non-genomic intracellular events that requires the interaction of ERα with the G protein Gα13 with 
the following involvement of the ubiquitous cytoskeletal modulator RhoA and of the Rho-
associated kinase, ROCK, which is responsible for the phosphorylation of moesin  (13). 
 
Moesin belongs to the ezrin-radixin-moesin (ERM) family of actin-binding proteins (15). By 
interacting with actin, activated ERMs induce actin de-polymerization and re-assembly toward the 
cell membrane edge, supporting the formation of cortical actin complexes (16). These complexes 
help the formation of molecular bridges between the actin cytoskeleton, integrins and focal 
adhesion complexes within ruffles and pseudopodia and are critical for cell movement (12). 
 
Ezrin, another member of the ezrin/radixin/moesin (ERM) family, is over-expressed in highly 
aggressive sarcomas (14, 17), as well as in breast cancer, being associated with higher metastasis 
rate (18). In addition, ezrin expression is induced by estrogens in ovarian cancer cells (19) 
suggesting that ERM proteins might have important functions in cancer progression and/or 
metastasis. 
 
In addition, a large amount of literature supports a key role of the Rho family of GTPases (Rho, Rac 
and CDC42) in co-ordinately regulating the polymerization of the actin cytoskeleton and of focal 
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adhesion turnover during cell migration (20) through the activation of different downstream 
effectors such as PI3K (phosphoinositide-3 kinase), PTEN phosphatase (wich converts 
phosphoinositides PIP3 into PIP2) and the WASP (Wiskott-Aldrich syndrome protein) family of 
proteins. The discovery of this group of cytoskeletal-regulatory proteins has contributed to clarify 
the molecular basis of cell movement. Indeed, signaling from Rho small GTPases to the Arp2/3 
complex, the WASP family members WASP, N-WASP and WAVE promote the formation and 
branching of actin filaments (21). Furthermore, estrogen might play a pivotal role in the process of 
tumour invasion through the induction of a FAK-dependent intracellular cascade (22). 
 
Estrogen administration to breast cancer cells leads to estrogen receptor-α (ERα) membrane 
translocation and to the rapid formation of such specialized cell membrane structures (23). Similar 
effects are found in human endothelial cells, where estrogen alters the cytoskeleton and increases 
cell migration through the activation of the actin binding protein, moesin (13). In this paper we 
study the effects of estradiol on the migration and invasion of ER+ or ER- breast cancer cells and 
we relate these observations to actin remodeling and to the activation of moesin and we characterize 
the signaling steps involved in these actions. In addition, we study the expression and sub-cellular 
localization of wild type and activated moesin in normal breast tissue, benign breast disorders as 
well as in ER+ and ER- invasive breast carcinomas, highlighting the relationship with lymph node 
metastasis. 
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MATERIALS AND METHODS 
 
Cell cultures and treatments 
The human breast carcinoma cell line T47-D and MDA-MB-468 were obtained from the American 
Type Culture Collection. T47-D cells were grown in RPMI 1640 supplemented with L-glutamine 
(2mM), 10% fetal bovine serum. MDA-MB-468 cells were cultured in McCoy’s 5A medium with 
L-glutamine (2mM) and 10% fetal bovine serum. Before treatments, both breast cancer cells lines 
were kept 24 hours in medium containing steroid-deprived FBS. Before experiments investigating 
non-transcriptional effects, cancer cells were kept in medium containing no FBS for 8 hours. 
Whenever an inhibitor was used, the compound was added 30 minutes before starting the 
treatments. 17β-estradiol, 17β-estradiol-BSA, tamoxifen, PTX, Y-27632, PD98059, L-NAME and 
wortmannin were from Sigma-Aldrich (Saint-Louis, MO), ICI 182,780, PPT and DPN were 
obtained by Tocris Cookson (Avonmouth, UK). 
 
Immunoblottings 
Cell lysates were separated by SDS-PAGE. Antibodies used were: moesin (clone 38, Transduction 
Laboratories, Lexington, KY), Thr558-P-moesin (sc-12895, Santa Cruz Biotechnology, Santa Cruz, 
CA), ERα (TE111, NeoMarkers, Union City, CA), ERβ (N-19, Santa Cruz), ROCK-2 (C-20, Santa 
Cruz), Gα13 (A-20, Santa Cruz), RhoA (26C4, Santa Cruz). Primary and secondary Abs were 
incubated with standard technique. Immunodetection was accomplished with enhanced 
chemiluminescence. 
 
Cell immunofluorescence 
T47-D cells were grown on coverslips and exposed to treatments. Cells were fixed and 
permeabilized with methanol at -20°C for 10 min. Blocking was performed with 3% normal serum 
for 20 min. Cells were incubated with antibodies against human moesin (clone 38, Transduction 
Laboratories) or with Texas Red-phalloidin (Sigma). The nuclei were counterstained with or 4'-6-
diamidino-2-phenylindole (DAPI) (Sigma) and mounted with Vectashield mounting medium 
(Vector Laboratories, Burlingame, CA). Immunofluorescence was visualized using an Olympus 
BX41 microscope and recorded with a high-resolution DP70 Olympus digital camera. After 
conversion to greyscale images, the cell membrane thickness and the gray levels of the extracellular area, 
cell membrane as well as cytoplasm were quantified using the Leica QWin image analysis and image 
processing software (Leica Microsystems, Wetzlar, Germany). 
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Co-immunoprecipitation assays 
HUVEC were harvested in 100 mM Tris-HCl, pH 6.8, 4% SDS, 20% glycerol, 1 mM Na3VO4, 1 
mM NaF, and 1 mM PMSF. Equal amounts of cell lysates were incubated with 1 µg of precipitating 
Ab (ERα, ROCK-2 or Gα13) for 1 hour at 4°C under gentle agitation. 25 µL of a 1:1 protein A-
agarose slurry were added, and the samples were rolled at 4°C for another hour. The samples were 
then pelleted, washed, and resuspended in 50 µL of 2X Laemmli buffer for immunoblotting. 
 
Kinase assays 
T47-D cells were harvested in 20 mM Tris-HCl, 10 mM EDTA, 100 mM NaCl, 0.5% IGEPAL, 0.1 
mg/mL PMSF. Equal amounts of cell lysates were immunoprecipitated with an Ab vs. ERα or 
ROCK-2. The IPs were washed three times with 20 mM Tris-HCl,10 mM  EDTA, 150 mM NaCl 
0.1% IGEPAL, 0.1 mg/mL PMSF. Two additional washes were performed in kinase assay buffer 
(20 mM MOPS, 25 mM β-glycerophosphate, 5 mM EGTA, 1 mM DTT) and the samples were 
therefore resuspended in this buffer. 5 µg of de-phosphorylated myelin basic protein (Upstate, Lake 
Placid, NY) together with 500 µM ATP and 75 mM MgCl2 were added to each sample and the 
reaction was started putting the samples at 30°C for 20 min. The reaction was stopped on ice and by 
resuspending the samples in Laemmli Buffer. The samples were separated with SDS-PAGE and 
western analysis was performed using an Ab recognizing Thr98-P-myelin Basic Protein. 
 
Rho Activity Assay 
T47-D cells were treated and harvested in Mg2+ Lysis/Wash Buffer (125 mM HEPES, pH 7.5, 750 
mM NaCl, 5% Igepal CA-630, 50 mM MgCl2, 5 mM EDTA and 10% glycerol). 1 µg of proteins 
were used to pull-down active, GTP-bound, RhoA using Rhotekin-GSH-agarose. The IPs were 
washed with Mg2+ Lysis/Wash Buffer and therefore resuspended in 2X Laemmli buffer. The IPs 
were separated on a denaturing acrylamide gel and western analysis with an anti-RhoA Ab was 
performed. 
 
Transient transfections 
T47-D cells were transfected with each plasmid (15 µg) using the Lipofectin reagent (Invitrogen, 
Carlsbad, CA) according to the manufacturer’s instructions. The transfected plasmids were: Gα13 
Q226L, Gα13 Q226L/D294N, RhoA T19 and RhoA G14V, Ras G12V and Ras S17N. All the inserts 
were cloned in pcDNA3.1+. The constructs were obtained from the Guthrie cDNA Resource Center 
(www.cdna.org). As control, parallel cells were transfected with empty pcDNA3.1+ plasmid. Cells 
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(60-70% confluent) were treated 24 h after transfection and cellular extracts were prepared 
according to the experiments to be performed. 
 
Gene silencing with RNA interference 
Two synthetic small interfering RNA targeting estrogen receptor α (siRNA SMARTpool ESR1, 
Dharmacon, USA) were used at the final concentration of 100 nM to silence ERα according to the 
manufacturer’s instructions. T47-D breast cancer cells were treated 60 hours after siRNA 
transfection. The efficacy of gene silencing was checked with western analysis and found to be 
optimal at 60 hours. 
 
Moesin silencing with antisense oligonucleotides 
Validated antisense phosphorotioate oligonucleotides (S-modified) (PONs) complementary to the 
1-15 position of the human moesin gene coding region [31] were obtained. The sequence was 5’-
TACGGGTTTTGCTAG-3’ for moesin antisense PON. The complementary sense PON was used as 
control (5’-CTAGCAAAACCCGTA-3’). PONs transfections were performed on sub-confluent 
T47-D breast cancer cells. PONs were resuspended in serum-free medium with 2% Lipofectin 
(Invitrogen) and added to the culture medium every 12 hours at the final concentration of 4 µM. 
Every 24 hours T47-D cells were washed and fresh medium supplemented with 4 µM of PONs was 
added. Moesin silencing was assessed through protein analysis up to 72 hours following 
transfection. 
 
Cell migration assay 
Cell migration was assayed with razor scrape assays. Briefly, a razor blade was pressed through the 
confluent T47-D breast cancer cell monolayer into the plastic plate to mark the starting line. T47-D 
cells were swept away on one side of that line. Cells were washed, and 2.0 mL of DMEM 
containing steroid-deprived FBS and gelatin (1 mg/mL) were added. Cytosine β-D-
arabinofuranoside hydrochloride (Sigma) (10 µM), a selective inhibitor of DNA synthesis which 
doesn’t inhibit RNA synthesis was used 1 h before the test substance was added. Migration was 
monitored for 48 hours. Every 12 h fresh medium and treatment were replaced. Cells were digitally 
imaged and migration distance was measured by using phase-contrast microscopy. 
 
Cell invasion assay 
Cell invasion were assayed using the BD BioCoatTM Growth Factor Reduced (GFR) MatrigelTM 
Invasion Chamber (BD Bioscience, USA). In brief, after rehydrating the GFR Matrigel inserts, the 
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test substance was added to the wells. An equal number of Control Inserts (no GFR Matrigel 
coating) were prepared as control. 0.5 mL of T47-D cell suspension (2.5 x 104 cells/mL) were 
added to the inside of the inserts. The chambers were incubated for 24 h at 37°C, 5% CO2 
atmosphere. After incubation, the non-invading cells were removed from the upper surface of the 
membrane using cotton tipped swabs. Then the cells on the lower surface of the membrane were 
stained with Diff-Quick stain. The invading cells were observed and photographed under the 
microscope at 100 X magnification. Cells were counted in the central field of triplicate membranes. 
The invasion index was calculated as the % invasion test cell/% invasion control cell. 
 
Tissue specimens 
Wild-type and phosphorylated-moesin expression was investigated  in  20 ductal  invasive breast  
adenocarcinomas, stage pT1c. Five of these were ER+/N+, 5 were ER+/N-, 5 were ER+/N+ and 5 
were ER-/N-. In addition, we also evaluated moesin and P-moesin in benign breast fibroadenomas 
(n=5) as well as in normal breast tissue (n=5). Samples were collected according to conventional 
histopathological diagnostic protocols and were fixed in 10% buffered formalin, embedded in 
paraffin, and stained with hematoxylin-eosin. Histological diagnosis and grading were performed 
according the World Health Organization Classification of Tumors (2002), and staging was 
determined according to the TNM system. 
 
Immunohistochemistry  
Histological sections of 4 µm were mounted on silanized slides and allowed to dry for 1 h at room 
temperature (RT), followed by 1 h incubation in an oven at 60°C. Briefly, after deparaffination and 
rehydration, epitope retrieval was performed by immersing slides in DAKO Epitope Retrival 
Solution (0.01 M citrate buffer, pH 6.0) in a water bath at 98°C for 40 minutes followed by  a 20 
minutes cool-down period at RT. The working dilution for the anti-human moesin monoclonal 
antibody (clone 38; BD Biosciences) was 1:50. P-moesin was evaluated with anti-P-moesin goat 
polyclonal antibody (Santa Cruz) at 1:50 dilution. The sections were incubated with primary 
antibodies for 1 hour at RT. The DAKO EnVision detection system kit was employed to detect 
moesin, instead for P-moesin the DAKO LSAB+ was used. Moesin and P-moesin expression were 
scored as positive when there was cytoplasmic, membrane or both cytoplasmic and membrane 
immunostaining. Staining scores were established semi-quantitatively from the percentage of 
Moesin+ and P-moesin+ cells and the staining intensity. Tumors were graded as negative (<1% 
positive cells), focal (low intensity, with >1% to < 30% positive cells), intense (moderate or high 
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intensity with diffused positive cells). Staining patterns were independently adjudicated by two 
pathologists.  
 
G-actin /F-actin assay 
The G-actin/F-actin assay kit was purchased from Cytoskeleton Inc (# BK037, Denver, USA). This kit is 
used to determine accurately the amount of filamentous actin (F-actin) content versus free globular-actin (G-
actin) content in a cell population. In brief, confluent T47-D cells were harvested with lysis at 37°C and F-
actin stabilization buffer (50 mM PIPES, 50 mM KCl, 5 mM MgCl2, 5 mM EGTA, 5% glycerol, 0.1% 
Nonidet P40, 0.1% Triton X-100, 0.1% Tween 20, 0.1% 2-mercapto-ethanol, 0.001% antifoam C, 1 mM 
ATP) after treatments. Total protein concentration was determined by standard method. Positive and 
negative controls were set by adding F-actin enhancing solution (phalloidin, 1 µM) or F-actin 
depolymerization solution (10 µM cytochalasin-D) to the lysates, respectively. The lysates were incubated at 
37°C for 10 min, followed by a centrifuge at 2000 rpm for 5 min to pellet and discard unbroken cells. 
Supernatant were centrifuged at 10,000 × g for 1 h at 37°C. After that, supernatant and pellet were both 
collected. Pellets were resuspended to the same volume as the supernatant using ice cold distilled water plus 
F-actin depolymerization solution (10 µM cytochalasin-D) and put on ice for 1 h to dissociate F-actin. 
According to the protein concentration previously measured, equivalent volumes of supernatant and 
dissolved pellet were loaded to run Western blot and G-actin/F-actin ratio was quantified using a quantitative 
digital imaging system. 
 
Statistical analysis 
All values are expressed as mean ± SD. Statistical differences between mean values were 
determined by ANOVA, followed by the Fisher’s protected least significance difference (PLSD). 
The χ2 test, Fisher's exact test  were used to evaluate the significance of the expression pattern of 
moesin and p-moesin and the clinical and pathological parameters with version 12 of the SPSS 
software package (SPSS Inc, IL, USA). A value of P <0.05 was considered significant. 
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RESULTS 
 
Estrogen receptor activation induces a rapid cytoskeletal rearrangement and the development of 
specialized membrane structures 
 
To assess the potential effect of estrogen receptor (ER) recruitment on breast cancer cell movement, 
we studied the morphological changes of the actin cytoskeleton in ER+ T47-D cells exposed to 
estradiol. Unstimulated cells displayed mainly longitudinally-arranged actin fibres in the cytoplasm 
(Fig. 1A). Recruitment of ER with 17β-estradiol (E2, 10 nM) resulted in a rapid change in actin 
organization, with a remodeling of the fibres toward the cell membrane edge (Fig. 1A). Plus, 
exposure to E2 was associated with the formation of specialized membrane structures linked to cell 
attachment to the extracellular matrix and to cell movement, such as pseudopodia and membrane 
ruffles (Fig. 1A). This phenomenon was time-dependent and transient, being maximal after 15-20 
minutes and then progressively reversing to the basal arrangement between 30 and 60 minutes (Fig. 
1A). The remodeling of actin fibres and the morphological changes of the membrane were 
quantified by assessing the intensity of the actin fluorescence after conversion of the coloured 
pixels to greyscale using the Leica QWin image analysis and processing software. This analysis was 
performed selecting random boxes including the extra- and intra-cellular space across the membrane, and the 
linear intensity of the signal was spatially recorded. We sampled three areas per each cell, and we repeated 
this on 30 different cells per experimental condition. The graphs in Fig. 1A show sample boxes used for the 
measure. These measures allowed to identify the thickness of the membrane, that is shown throughout the 
time-course in Fig. 1B, as well as the mean ± SD intensity of the actin staining in the membrane, in the 
cytosol, as well as the membrane/cytosol ratio (Fig. 1C). 
 
Estrogen receptor recruitment turns into a rapid activation of the actin-regulatory protein moesin 
 
Activation of ER with E2 turned into a rapid increase of Thr558 phosphorylation (which corresponds 
to activation) [15,16] of the actin-binding protein moesin (Fig. 2A). The activation of moesin by E2 
follows the same kinetics as actin rearrangement (Fig. 2A) and was achieved through extra-nuclear 
pathways, as no changes of cell immunoreactive moesin were found (Fig. 2A). In estrogen-receptor 
negative MDA-MB-468 breast cancer cells moesin was constitutively phosphorylated and exposure 
to estradiol did not alter this activation any further, suggesting that this protein may be basally over-
active in these cells (Fig. 2B). 
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In T47-D breast cancer cells, the activation of moesin was related to the concentration of E2 and 
was triggered by physiological amounts of the steroid (Fig. 2C), whereas in MDA-MB-468 cells no 
change in moesin phosphorylation was detected throughout all the range of estradiol concentrations 
(Fig. 2D). 
 
Moesin is required for estrogen receptor-induced actin remodeling
To assess whether moesin is required for the estrogen receptor-dependent cytoskeletal 
rearrangement in T47-D cells, we silenced moesin by transfection of specific antisense 
phosphorotioate oligonucleotides (PONs) and observed the actions of E2 on actin rearrangement. 
Moesin expression was significantly reduced when T47-D breast cancer cells were transfected with 
antisense moesin PONs for 72 h (Fig. 3A).  In moesin-silenced cells, E2 failed to induce a rapid 
actin reorganization, to induce increased in membrane thickness and to increase the ratio of 
membrane/cytosol actin staining (Fig. 3B-C). Furthermore, moesin-silenced cells did not develop 
specialized membrane structures in the presence of E2 (Fig. 3B). As control, E2 was fully effective 
in cells transfected with sense (inactive) moesin PONs (Fig. 3B-C). 
 
Estrogen activates moesin via ERα 
Moesin activation induced by E2 in T47-D cells was prevented by the addition of the pure ER 
antagonist ICI 182,780 (ICI, 1 µM) (Fig. 4A), indicating that ER is required. ICI 182,780 had no 
inhibitory effect on moesin phosphorylation in ER- MDA-MB-468 cells, supporting the concept 
that in these cells the recruitment of this protein does not require the presence of ER (Fig. 4B). 
 
To identify which ER isoform is required for the signaling of estrogen to moesin, we treated T47-D 
cells with estradiol or with the preferential ERα agonist 4,4’,4”-(4-propyl-[1H]-pyrazole-1,3,5-
triyl)trisphenol  (PPT, 1nM) [17] or with the ERβ agonist 2,3-bis(4-hydroxyphenil)-propionitrile 
(DPN, 1nM)[18]. Moesin activation was detected only in the presence of estradiol or PPT, 
suggesting that ERα supports the signaling to moesin, while ERβ is not required (Fig. 4C). 
 
Since the ER isoform selectivity of PPT and DPN is not absolute (at higher concentrations they 
bind to some extent both ERα and ERβ), we knocked out ERα in T47-D cells with targeted small 
interfering RNAs (siRNAs). Transfection of the ERα siRNAs resulted in a clear reduction of ERα 
expression, along with a dramatic decrease of the phosphorylation of moesin during exposure to 
estrogen (Fig. 4D). This happened in the absence of modifications of the expression of moesin or 
ERβ (Fig. 4D), supporting the hypothesis that ERα drives the signaling of estradiol to moesin. 
 12
Maria Silvia Giretti                                                                        ERα, moesin and BC movement 
 
ERα signals to moesin through a Gα13- and RhoA-dependent signaling pathway 
In the search for the signaling pathways through which ERα leads to moesin activation in breast 
cancer cells, we used different pharmacological inhibitors linked to ERα or moesin. PD98059 (PD, 
5 µM), an inhibitor of mitogen-activated protein kinases (MAPK) and wortmannin (WM, 30 nM), 
an inhibitor of phosphatidylinositol 3-OH kinase (PI3K), did not alter the estradiol-induced moesin 
phosphorylation (Fig. 5A). Instead, the G protein inhibitor, pertussis toxin (PTX, 100 ng/mL) 
significantly inhibited moesin phosphorylation induced by E2 (Fig. 5A). Moreover, the membrane-
impermeable estradiol-bovine serum albumin conjugate (E2-BSA, 10 nM) triggered moesin 
activation similar to normal E2 (Fig. 5A). These findings suggest that a G protein-dependent, cell-
membrane initiated mechanism mediates the signaling of ERα to moesin and to the actin 
cytoskeleton. 
 
We previously showed that ERα is able to interact with the G protein, Gα13, that controls the small 
GTPase RhoA and its effector, Rho-associated kinase (ROCK) [8]. This signaling cascade is 
implicated in the control of the cytoskeleton in human vascular cells [8]. With co-
immunoprecipitation assays we found that in T47-D cells estradiol triggers a direct association of 
ERα with Gα13 which is prevented by ICI 182,780 (Fig. 5B). In parallel, no co-
immunoprecipitation of ERβ with Gα13 was found (Fig. 5B). 
 
By assaying RhoA GTP-binding activity, we found that RhoA is activated in T47-D cells by rapid 
exposure to estradiol or to the membrane-impermeable estradiol-BSA (Fig. 5C). RhoA activation 
was prevented by ER antagonism with ICI 182,780 and by interference with G proteins with PTX 
(Fig. 5C). The ERα-selective agonist PPT was associated with a strong activation of RhoA (Fig. 
5C). The ERβ-preferential ligand, DPN, was also found to increase RhoA GTP-binding, although to 
a lesser extent (Fig. 5C). 
 
To further test the requirement of Gα13 and RhoA for ERα-induced moesin activation in T47-D 
breast cancer cells, we performed transient transfections with Gα13 (Gα13 Q226L) or RhoA (RhoA 
G14V) constitutively active mutated constructs or with Gα13 (Gα13 Q226L/D294N) or RhoA 
(RhoA T19N) dominant negative constructs (Fig. 5D). Breast cancer cells transfected with 
constitutively active constructs showed an over-active moesin phosphorylation that was 
independent of estradiol (Fig. 5D). Instead, dominant negative Gα13 or RhoA constructs 
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significantly inhibited the estradiol-induced moesin activation (Fig. 5D). Overall, these results show 
that Gα13 and RhoA are implicated in the signaling of ERα to moesin in breast cancer cells. 
 
ERα and  moesin phosphorylation: role of the Rho-associated kinase (ROCK-2) 
ROCK-2 phosphorylates moesin on Thr558 in different cell types, leading to filamentous actin fibers 
polymerization [19]. Pre-incubation of T47-D breast cancer cells with the specific Rho-kinase 
inhibitor, Y-27632 (Y-27632, 10 µM) prevented the activation of moesin by estradiol, implying that 
ROCK-2 is required for estrogen signaling to moesin in breast cancer cells (Fig 6A). 
 
In agreement, ER activation resulted in increased ROCK-2 kinase activity in T47-D breast cancer 
cells (Fig. 6B). This was suppressed by ICI 182,780, Y-27632 as well as by PTX (Fig. 6B), 
indicating that ER recruitment turns into a G protein-dependent ROCK-2 activation. 
 
In addition, we previously showed that ERα is able to interact with and directly activate ROCK-2 in 
human endothelial cells [8].  In T47-D breast cancer cells, an enhanced interaction between ERα 
and ROCK-2 was found with co-immunoprecipitation experiments in cells exposed to E2 (Fig. 6C-
D). This protein-protein interaction was blocked by ICI 182,780 but not by PTX (Fig. 6C-D), 
suggesting that this may represent an additional mechanism for ERα-dependent ROCK-2 
recruitment. To check whether the interaction with ERα turns ROCK-2 into an active status, we 
performed kinase assays using ERα immunoprecipitates (IPs) to target for Thr-phosphorylation the 
bait protein, myelin basic protein (MBP). ERα immunoprecipitates obtained from T47-D cells 
treated with estradiol induced MBP phosphorylation (Fig. 6E). ICI 182,780 and the ROCK-2 
inhibitor Y-27632 counteracted this activation (Fig. 6E), confirming that ROCK-2 interacting with 
the ligand-engaged ERα is functionally activated. Consistently with the previous results, PTX did 
not reduce the activity of the ERα-associated-ROCK-2 (Fig. 6E), further suggesting the presence of 
two separate pathways of activation of ROCK-2 by ERα: one is G protein-dependent, while the 
second relies on a direct ERα/ROCK-2 interaction, which is not sensitive to PTX. 
 
Gα13, RhoA and ROCK-2 are necessary for the ER-dependent actin remodeling 
To investigate whether Gα13, RhoA or ROCK-2 are required for the ER-induced cytoskeletal 
remodeling, we studied the architecture of actin fibers while transfecting T47-D cells with the Gα13 
or RhoA mutated constructs or in the presence of the ROCK-2 inhibitor Y-27632. Both the Gα13 
and RhoA constitutively active constructs triggered a visible actin cytoskeleton remodeling with 
generation of membrane protrusions, resulting in enhanced interaction of T47-D cells with the 
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extracellular matrix and with nearby cells (Fig. 7A). Estradiol did not modify the cytoskeletal 
structure any further in these cells (Fig. 7A). In parallel, the dominant negative Gα13 and RhoA 
constructs completely abrogated the modifications of actin and cell morphology induced by 
estrogen (Fig. 7A). Moreover, the inhibition of ROCK with Y-27632 completely prevented the 
effect of estradiol on cytoskeleton remodeling (Fig. 7A). These changes were reflected in the 
measurements of the mean membrane intensity and membrane/cytosol ratio (Fig. 7B). 
 
The changes in actin spatial organization were accompanied by parallel modifications of the ratio 
between globular and fibrillar actin. At baseline, actin fibers predominantly existed as monomers 
(G-actin) (Fig. 7C). After treatment with E2 for 15 min, a visible shift from G to F actin was seen 
(Fig. 7C), indicating that ER recruitment is linked to polymerization of G-actin into F-actin. The ER 
antagonist ICI 182,780, the G protein inhibitor, pertussis toxin (PTX) and the Rho-kinase inhibitor 
Y-12732 largely prevented the shift from G- to F-actin induced by estradiol (Fig. 7C). 
 
Recruitment of ER enhances breast cancer cell migration and invasion through a G 
protein/ROCK/moesin  pathway 
To address the question of the relevance of the ERα/Gα13/RhoA/ROCK/moesin signaling cascade 
on breast cancer cell movement, we pretreated T47-D or MDA-MB-468 (ER-) breast cancer cells 
with cytosine arabinoside (1-(β-D-arabino-furanosyl)-cytosine hydrochloride - Ara-C, 100µM), an 
inhibitor of DNA strand separation that prevents cell division, and we performed horizontal 
migration assays. Estradiol (E2, 10 nM) strongly enhanced the migration of T47-D cells (Fig. 8). 
This was largely prevented by ICI 182,780, PTX and Y-27632, as well as by moesin silencing with 
antisense oligonucleotides (Fig. 8). In addition, the selective estrogen receptor modulator tamoxifen 
(TAM, 10 nM) that is used in the adjuvant treatment of ER+ breast cancers, also reduced the 
migration of T47-D cells induced by E2 while being ineffective on its own (Fig. 8). 
 
In general, ER- MDA-MB-468 cells showed a stronger tendency to migrate in comparison to T47-
D cells and this was not affected by E2, ICI, PTX or tamoxifen (Fig. 9). However, the ROCK 
inhibitor, Y-27632, significantly decreased the migration of these cells (Fig. 9), suggesting that 
ROCK-2 may be overactive in MDA-MB-468 cells, and that this may enhance their ability to 
migrate. 
 
To test the impact of the ER-dependent signaling to moesin on breast cancer cell invasion we 
performed three-dimensional invasion assays using matrigel. Ara-C-pretreated cells showed an 
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enhanced invasion of the matrix in the presence of E2 or E2-BSA (Fig. 10). The effect of E2 was 
blocked by the ER-antagonist ICI 182,780, by PTX, by the ROCK-inhibitor Y-27632 as well as by 
tamoxifen (Fig. 10). In addition, transfection of moesin antisense PONs also resulted in impaired 
migration in the presence of estradiol (Fig. 10). 
 
Moesin and P-moesin sub-cellular localization in normal breast tissue, benign breast disease and 
invasive breast cancer 
To further characterize the biological role of moesin, we studied the sub-cellular distribution of 
wild-type moesin and activated moesin in normal and tumoral human breast tissues by 
immunochemistry.  
 
In normal human mammary ducts, stainings for wild-type and phosphorylated moesin were found 
on the apical surface of ductal epithelial cells (Fig. 11), consistent with the usual localization in 
polarized secretory cells [9]. In addition, both moesin and P-moesin stainings were present in 
occasional basal myo-epithelial elements and in endothelial cells (Fig. 11). Similar to normal breast 
tissue, in breast fibroadenomas (FAD) moesin and P-moesin were prominently localized at the cell 
membrane of epithelial elements (Fig. 11), along with occasional stromal and myo-epithelial cells. 
 
In addition, in order to characterize moesin and P-moesin expression and distribution in invasive 
breast cancers, we stained samples from human ductal carcinomas (tumor stage: pT1c - size 
between 1 and 2 cm - see table 1) and we compared the pattern of staining of ER positive or 
negative cancers, with or without lymph node metastasis. 
 
Different from normal breast tissues or fibroadenomas, invasive ductal carcinomas showed a 
deranged moesin and P-moesin cellular localization, with four main expression/distribution 
patterns. Some cancers showed a weak, focal expression of moesin (focal, less than 10% of the cells 
stain for moesin, Fig. 11). Other cancers instead showed an intense staining for moesin, but some 
had a strong expression of moesin at the cell membrane (Fig. 11), while others showed a mixed 
membrane/cytoplasmic staining (Fig. 11). Other tumors had instead a clear cytoplasmic moesin 
staining, in the absence of membrane localization (Fig. 11).  
 
There was no significant statistical difference in the association of the type of staining with lymph 
node metastasis status in ER+ or ER- cancers. However, ER- tumors showed a statistically 
significant difference vs. ER+ cancers in wild-type moesin localization, having consistently no 
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membrane-only staining while displaying a constant cytoplasmic moesin (table 1). In addition, 
although this was not significant, ER- cancers with lymph node metastasis tended to display more 
frequently a cytoplasmic-only moesin staining, without any membrane localization positioning 
(table 1). 
 
When P-moesin staining was studied, similar patterns of sub-cellular distribution were found in 
invasive cancers (focal vs. intense staining; membrane vs. membrane/cytoplasmic vs. cytoplasmic, 
Fig. 11), but there was no significant association with either ER or lymph node status (table 1). 
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DISCUSSION 
 
Estrogens act as promoters of cell proliferation and movement in different tissue types, including 
the breast (2). This action is particularly relevant in the presence of estrogen receptor positive 
(ER+) breast cancers, that are driven to grow, invade and metastasize by endogenous or exogenous 
estrogens (4, 31). For these reasons, understanding the basis through which estrogens drive cancer 
cells to interact with the extracellular environment to enact movement and invasion heralds 
profound biological and medical implications. 
 
We here show that estrogen enhances horizontal migration and invasion of three-dimensional 
matrices of ER+ breast cancer cells by recruiting the actin-binding protein, moesin. Moesin resides 
at the nexus of multiple pathways regulating cell attachment with the extracellular matrix and with 
nearby cells, cell motility and metastatic potential as well as cell survival. These functions are 
directed by moesin though the modulation of actin cytoskeleton/plasma membrane interactions. 
 
Moesin activation by estrogen in breast cancer cells is linked to the rapid and dynamic remodeling 
of the actin cytoskeleton and to the formation of specialized cell membrane structures, such as 
pseudopodia and ruffles, that are involved in the interaction with the extracellular matrix and 
required for cell movement (9, 12). These actions are consistent with our previous observation of 
improved wound healing due to enhanced endothelial cell movement in the presence of estrogens, 
linked to the activation of moesin (13), as well as with the recently reported activation of 
cytoskeletal remodeling and cell migration by estrogens in endometrial cancer (32). 
 
Our findings also strengthen the concept that the nongenomic signaling of estrogen receptor to 
ERM proteins and actin may be of general relevance for the determination of cell movement. 
Indeed, the actions described in this report occur within minutes without the need of activating gene 
expression (33) and are thereof dynamically shut off within 30 to 60 minutes. This makes sense in 
light of the established requirement of multiple, periodic, waves of actin remodeling and dynamic 
formation of anchorage sites to the extracellular matrix in order to accomplish cell movement (9, 
12).  
 
In addition, loss of stress fibers is associated with cancer cell transformation and metastasis (34). 
Thus, the cytoskeletal rearrangement induced by estradiol through moesin may in part explain the 
carcinogenic actions of this steroid in estrogen-sensitive breast cancers, along with the enhanced 
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metastatic behavior of such neoplasms in the presence of sex steroid hormones (35). In support of 
this, similar actions of estrogen linked to the regulation of the ERM protein ezrin have been 
described in estrogen-sensitive cancers (19, 36). 
 
ER- breast cancers, such as MDA-MB-468 cells, are not sensitive to estrogen administration in 
terms of moesin activation and cell migration. However, these cells display a basal hyper-activation 
of moesin. In addition, a direct inhibitor of moesin phosphorylation (ROCK inhibitor) is highly 
effective in reducing MDA-MB-468 cell horizontal migration. These findings are intriguing, as they 
suggest that sustained moesin activation by ROCK might be an important player in the metastatic 
behavior of ER- breast cancer cells. This fits with a previous report of a prominent expression of 
moesin in ER- human breast tumors, related to the tendency to metastasize (37). 
 
The mechanistic basis that supports estrogen signaling to moesin and the actin cytoskeleton is found 
in the recruitment of the Gα13/RhoA/ROCK pathway by ERα. Similarly to what previously found in 
human endothelial cells (13), estrogen-bound ERα dynamically interacts with the G protein Gα13 
and triggers its activation. This leads to the recruitment of the small GTPase RhoA and of its 
downstream effector, ROCK-2, which is responsible for moesin phosphorylation. These signaling 
intermediates, including moesin, are all required for actin remodeling as well as breast cancer cell 
migration and invasion. Interestingly, ERβ does not support the interaction with Gα13 nor it 
activates moesin. Overall, this further establishes the nongenomic ERα/Gα13/RhoA/ROCK/moesin 
signaling cascade as an important controller of cell movement by estrogen in different cell types, 
including cancer cells. 
 
We also find that human breast cancers display a deranged over-expression and over-activation of 
moesin respect to normal breast tissues and/or benign fibroadenomas. Although our observation is 
only descriptive and limited to a small sample of patients, it is remarkable to find some variations in 
the sub-cellular localization of moesin in different cancer types. For instance, we find a trend 
towards the loss of membrane localization of moesin in ER- vs. ER+ cancers, which calls for future 
work to further characterize if the overall expression of this protein or its sub-cellular positioning 
might be associated with different cancer biology or behavior. This would be consistent with what 
is already known for the parent ERM protein, ezrin. Ezrin has been consistently found to be over-
expressed in invasive epithelial neoplasia, such as in estrogen-sensitive endometrial (38, 39) and 
breast carcinomas (18, 40), and in highly aggressive sarcomas as well (14, 17), being related in 
many of these studies to the presence of tumor metastasis. 
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In conclusion, the present results suggest that within the broader range of actions of estrogen 
receptors, nongenomic signaling to the actin cytoskeleton through the 
ERα/Gα13/RhoA/ROCK/moesin cascade is relevant for the determination of estrogen-dependent 
breast cancer cell movement and invasion that are related to cancer metastasis. The characterization 
of these actions increase our understanding of the effects of estrogens on breast cancer progression 
and might be useful to develop new tools to interfere with the ability to diffuse locally or at distant 
sites of ER+ or ER- breast carcinomas. 
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TABLE LEGEND 
 
Table 1. Immunohistochemical analysis of moesin and P-moesin in normal breast tissue, 
benign breast disease and breast cancers. Negative indicates visible staining in less than 1% of 
the cells. Focal indicates staining in less than 30% cells. Intense indicates diffused staining 
throughout the tissue. Membrane (MEM) indicates staining exclusively localized to the cell 
membrane in more than 90% of the cells; membrane/cytoplasm (MEM/CYTO) indicates staining 
both on the cell membrane as well as in the cytoplasm in more than 90% of the cells; cytoplasm 
(CYTO) indicates staining of the cytoplasm without any evident membrane staining in more than 
90% of the cells. Staining patterns were independently adjudicated by two pathologists. 
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FIGURE LEGENDS 
 
Fig. 1. Recruitment of ER induces a dynamic remodeling of the actin cytoskeleton and of the 
cell membrane in T47-D breast cancer cells. A) T47-D cells were treated for different times with 
E2 (10 nM). Actin fibers were stained with phalloidin linked to Texas Red (red labeling) and nuclei 
were counterstained with DAPI (blue labeling). Immunofluorescent analysis reveals the dynamic 
modifications of actin fibers through the time-course and the formation of specialized cell 
membrane structures. Green arrows indicate longitudinal fibers; light blue arrows indicate 
membrane ruffles; yellow arrows indicate pseudopodia. Rectangles indicate the analyzed area which 
was demonstrated by the corresponding upper graph. In the graph, the longitudinal axis represents the gray 
level and the horizontal axis indicates pixels. Yellow, red and blue areas indicate the extracellular, plasma 
membrane and cytoplasmic fraction, respectively. B and C) Analytic results obtained by using Leica QWin 
image analysis and processing software showing the mean thickness of the cell membrane as well as the 
intensity of actin staining in the cytoplasm, membrane or extracellular compartment after treatment with E2 
(10 nM) for different times. The results are derived from the sampling of five areas of the cell membrane of 
thirty different random cells. The areas of minimum and maximum cell membrane thickness were always 
included. The results are the mean ± SD of the measurements. In C) * = p < 0.05 vs. Basal condition (0 min). 
 
Fig. 2. ER recruitment results in the activation of the actin-binding protein, moesin. Protein 
extracts from T47-D (A and C) and MDA-MB-468 (B and D) breast cancer cells treated for 
different times with 10 nM E2 (A and B) or for 15 min with increasing concentrations of E2 (C 
and D) were assayed with western analysis for their overall content of wild type moesin (moesin) 
or Thr558-phosphorylated moesin (P-moesin). 
 
Fig. 3. Moesin is required for estrogen-induced cytoskeletal remodeling. A) T47-D cells were 
transiently transfected with antisense (2 µM antisense MOESIN) moesin phosphorotioate 
oligonucleotides (PONs) for 0, 60 or 72 hours and moesin expression was assayed with western 
analysis. B and C) T47-D cells were transiently transfected with vehicle or antisense (2 µM 
antisense MOESIN) or sense (2 µM sense MOESIN) moesin phosphorotioate oligonucleotides 
(PONs) for 72 hours and then treated for 15 min with 10 nM E2. Moesin expression was checked 
by staining with a specific Ab linked to FITC (green labeling). Actin fibers were stained with 
phalloidin-Texas Red (red labeling) and nuclei were counterstained with DAPI (blue labeling). F) 
shows the analytic results obtained by using Leica QWin image analysis and processing software 
showing the mean thickness of the cell membrane as well as the intensity of actin and moesin 
staining in the cytoplasm, membrane or extracellular compartment. The results are derived from the 
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sampling of five areas of the cell membrane of thirty different random cells. The areas of minimum 
and maximum cell membrane thickness were always included. The results are the mean ± SD of the 
measurements. * = p < 0.05 vs. vehicle-transfected control. 
 
Fig. 4. Estrogen signals to moesin via ERα. T47-D (A and C) or MDA-MB-468 (B) cells were treated for 
15 minutes with either E2 (10 nM), the preferential ERα agonist PPT (10 nM) or the preferential ERβ 
agonist, DPN (10 nM), in the presence or absence of the ER antagonist, ICI 182,780 (1 µM). Western 
analyses of wild-type moesin (moesin) or Thr558-phosphorylated moesin (P-moesin) were performed. D) 
T47-D cells were transfected with siRNAs vs. ERα (siRNA ERα), with scrambled siRNAs or with vehicle, 
and protein analysis for ERα, ERβ, wild-type moesin (moesin) or Thr558-phosphorylated moesin (P-moesin) 
was performed on cell lysates after treatment for 15 min with vehicle or 10 nM E2. 
 
Fig. 5. ERα signals to moesin via Gα13 and RhoA. A) T47-D cells were exposed for 15 min to 10 nM E2 
or to E2 conjugated to bovine serum albumin (E2-BSA; 10 nM), in the presence or absence of the ER 
antagonist ICI 182,720 (ICI; 1 µM), of the MAPK inhibitor PD98059 (PD; 5 µM), of the PI3 kinase inhibitor 
wortmannin (WM; 30 nM) or of the G protein inhibitor, PTX (100 ng/ml). Wild-type moesin (moesin) or 
Thr558-phosphorylated moesin (P-moesin) were assayed in cell extracts. B) T47-D cells were treated for 15 
min with 10 nM E2 in the presence or absence of ICI 182,720 (ICI, 1 µM). Cell protein extracts were 
immunoprecipitated with an Ab. vs. Gα13 and  the IPs were assayed for co-immunoprecipitation of ERβ or 
ERα. The membrane was re-blotted for Gα13 to show equal input. C) RhoA activity was assayed in T47-D 
treated for 15 min with 10 nM E2, E2 conjugated to BSA (E2-BSA, 10 nM), the ERα-preferential ligand 
PPT (10 nM) or the ERβ-preferential agonist DPN (10 nM) in the presence or absence of ICI 182,720 (ICI, 1 
µM) or PTX (100 ng/ml). Active, GTP-bound, RhoA was precipitated with Rhotekin, and a western analysis 
for RhoA was then performed. D) Whole-cell extracts were assayed for wild-type (moesin) or for Thr558-
phosphorylated (P-moesin) moesin content after transfection with empty vector or with Gα13 or RhoA 
constitutively active (Gα13 CA and RhoA CA) or dominant-negative (Gα13 DN and RhoA DN) constructs, in 
the presence or absence of E2 (10 nM; 15 min). 
 
Fig. 6. ERα recruits the Rho-associated kinase, ROCK-2. T47-D cells were treated for 15 min with 10 
nM E2 in the presence or absence of the ROCK-2 inhibitor, Y-27632 (Y; 10 µM), ICI 182,720 (ICI; 1 µM), 
or PTX (100 ng/ml). A) Wild-type moesin (moesin) or Thr558-phosphorylated (P-moesin) moesin were 
assayed in breast cancer cell extracts. B) Breast cancer cell protein extracts were immunoprecipitated with an 
Ab. vs. ROCK-2 and the IPs were used to perform kinase assays using de-phosphorylated myelin basic 
protein (MBP) as a bait. The lower box shows phosphorylation of MBP, the upper box shows the re-blot of 
the membranes for the immunoprecipitated protein. C and D) Breast cancer cell protein extracts were 
immunoprecipitated with an Ab. vs. ERα (C) or ROCK-2 (D) and co-immunoprecipitation of ROCK-2 or 
ERα was assayed with western analysis. The membranes were re-blotted for ERα or ROCK-2 to show equal 
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input. E) Breast cancer cell protein extracts were immunoprecipitated with an Ab. vs. ERα and the IPs were 
used to perform kinase assays using de-phosphorylated myelin basic protein (MBP) as a bait. The lower 
boxes show phosphorylation of MBP, the upper boxes show the re-blot of the membranes for the 
immunoprecipitated protein. 
 
Fig. 7. Actin remodeling by estrogen receptor requires Gα13, RhoA and ROCK-2. A) T47-D cells 
transiently transfected with either empty vector or with plasmids encoding for constitutively active or 
dominant-negative Gα13 (Gα13 CA or Gα13 DN) or RhoA (RhoA CA or RhoA DN) were treated for 15 min 
with 10 nM E2. Other cells also received a co-treatment with E2 (10 nM; 15 min) and the ROCK inhibitor 
Y-27632 (Y; 10 µM). Breast cancer cell actin fibers were stained with phalloidin linked to Texas Red, and 
nuclei were counterstained with DAPI. B) shows the analytic results obtained by using Leica QWin image 
analysis and processing software showing the mean thickness of the cell membrane as well as the intensity of 
actin staining in the cytoplasm, membrane or extracellular compartment. The results are derived from the 
sampling of five areas of the cell membrane of thirty different random cells. The areas of minimum and 
maximum cell membrane thickness were always included. The results are the mean ± SD of the 
measurements. * = p < 0.05 vs. vehicle-transfected control. C) shows the changes of  the amount of 
filamentous actin (F-actin, F) content versus free globular-actin (G-actin, G) content in T47-D cells after 
treatment with E2 (10 nM) for 15 min, in the presence or absence of ER antagonist ICI 182,720 (ICI; 1 µM), 
G protein inhibitor PTX (100 ng/ml) and ROCK-2 inhibitor Y-27632 (Y; 10 µM). Positive (Pos) and 
negative (Neg) controls were set by adding F-actin enhancing solution (phalloidin, 1 µM) or F-actin 
depolymerization solution (10 µM cytochalasin-D) to the lysates, respectively. 
 
Fig. 8. Role of the G protein/ROCK/moesin pathway for ER+ breast cancer cell migration. 
Steroid-deprived, growth synchronized ER+ T47-D cells were exposed to 10 nM E2, in the 
presence or absence of the ER antagonist ICI 182,720 (ICI; 1 µM), of the G protein inhibitor PTX 
(100 ng/ml), or of the ROCK-2 inhibitor, Y-27632 (Y; 10 µM) or of the selective estrogen receptor 
modulator (SERM) tamoxifen (TAM, 10 nM). In addition, some T47-D cells were treated with 10 
nM E2 in the presence or absence of transfection with sense (Sense; 2 µM) or antisense (AS; 2 µM) 
moesin phosphorotioate oligonucleotides (PONs). Breast cancer cells were scraped from the culture 
dish and the mean migration distance of the cells from the starting line was assayed after 48 h and 
expressed as mean ± SD. Representative images are shown and the mean ± SD of migration are 
shown in the bar graphs. * = p < 0.05 vs. E2. 
 
Fig. 9. Role of the G protein/ROCK/moesin pathway for ER- breast cancer cell migration. 
ER- MDA-MB-468 cells were exposed to 10 nM E2, in the presence or absence of the ER 
antagonist ICI 182,720 (ICI; 1 µM), of the G protein inhibitor PTX (100 ng/ml), or of the ROCK-2 
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inhibitor, Y-27632 (Y; 10 µM) or of the selective estrogen receptor modulator (SERM) tamoxifen 
(TAM, 10 nM). Breast cancer cells were scraped from the culture dish and the mean migration 
distance of the cells from the starting line was assayed after 48 h and expressed as mean ± SD. 
Representative images are shown and the mean ± SD of migration are shown in the bar graphs. * = 
p < 0.05 vs. control. 
 
Fig. 10. Role of the G protein/ROCK/moesin pathway for ER+ breast cancer cell invasion.  
Steroid-deprived, growth synchronized ER+ T47-D cells were exposed to 10 nM E2, or 10 nM E2-
BSA conjugate in the presence or absence of the ER antagonist ICI 182,720 (ICI; 1 µM), of the G 
protein inhibitor PTX (100 ng/ml), or of the ROCK-2 inhibitor, Y-27632 (Y; 10 µM) or of the 
selective estrogen receptor modulator (SERM) tamoxifen (TAM, 10 nM). In addition, some T47-D 
cells were treated with 10 nM E2 in the presence or absence of transfection with sense (Sense; 2 
µM) or antisense (AS; 2 µM) moesin phosphorotioate oligonucleotides (PONs). Breast cancer cell 
invasion through matrigel was assayed by using invasion chambers. Invading cells were counted in 
the central field of triplicate membranes. Invasion indexes and representative images in chambers 
with matrigel are shown. * = p < 0.05 vs. E2. 
 
Fig. 11. Moesin and P-moesin expression and sub-cellular localization in human normal 
breast tissue, benign fibroadenomas and breast cancers. Histological sections (4 µm) from 
normal mammary glands, fibroadenomas or ER positive (ER+) breast cancers were used to identify 
the expression and localization of moesin and P-moesin with immunochemistry. Wild-type moesin 
as well as Thr558-phosphorylated are shown as brown labeling. The figure displays sample images 
from the tumors analyzed in Table 1. Particularly, The normal breast tissue comes from Patient 2, 
the fibroadenomas is from patient 3. The breast cancer showing focal staining is that of patient 20, 
the cancer with membrane staining comes from patient 13. The cancer showing mixed 
membrane/cytoplasmic staining is from patient 17. The “high expression” cancer is from patient 12. 
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TABLE 1. 
 
NORMAL BREAST
SAMPLES MOESIN MEM MEM/CITO CYTO P-MOESIN MEM MEM/CITO CYTO
1 INTENSE x INTENSE x
2 INTENSE x INTENSE x
3 INTENSE x INTENSE x
4 INTENSE x INTENSE x
5 INTENSE x INTENSE x
FIBROADENOMAS
SAMPLES MOESIN MEM MEM/CITO CYTO P-MOESIN MEM MEM/CITO CYTO
1 INTENSE x INTENSE x
2 INTENSE x INTENSE x
3 INTENSE x INTENSE x
4 INTENSE x INTENSE x
5 INTENSE x INTENSE x
INVASIVE DUCTAL CARCINOMAS
SAMPLES DIAMETER pNx ER% MOESIN MEM MEM/CITO CYTO P-MOESIN MEM MEM/CITO CYTO
ER POSITIVE/LYMPH NODE POSITIVE
1 18 mm pN2a (7/16) 84% FOCAL x NEGATIVE
2 19 mm pN1m (1/8) 98% INTENSE x INTENSE x
3 15 mm pN1a (1/3) 98% INTENSE x INTENSE x
4 16 mm pN1a (2/24) 100% INTENSE x FOCAL x
5 16 mm pN3a (8/15) 95% INTENSE x FOCAL x
ER POSITIVE/LYMPH NODE NEGATIVE
1 14 mm 90% INTENSE x FOCAL x
2 15 mm 90% INTENSE x INTENSE x
3 10 mm 100% INTENSE x INTENSE x
4 15 mm 99% FOCAL x INTENSE x
5 18 mm 98% FOCAL x FOCAL x
ER NEGATIVE/LYMPH NODE POSITIVE
1 18 mm pN2a (7/16) 0% FOCAL x*
x*
x*
x*
x*
x*
x*
x*
x*
x*
NEGATIVE
2 17 mm pN1m (1/17) 0% INTENSE INTENSE x
3 11 mm pN1m (1/1) 0% INTENSE INTENSE x
4 17 mm pN1a (2/19) 0% INTENSE FOCAL x
5 13 mm pN3b (20/24) 0% INTENSE FOCAL x
ER NEGATIVE/LYMPH NODE NEGATIVE
1 8 mm 0% INTENSE NEGATIVE
2 16 mm 0% INTENSE FOCAL x
3 13 mm 0% INTENSE FOCAL x
4 15 mm 0% INTENSE NEGATIVE
5 12 mm 0% FOCAL INTENSE x  
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